Assembly Biosciences (ASMB) Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC lifted its stake in shares of Assembly Biosciences (NASDAQ:ASMB) by 3.7% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 189,700 shares of the biopharmaceutical company’s stock after acquiring an additional 6,700 shares during the period. Renaissance Technologies LLC owned approximately 0.94% of Assembly Biosciences worth $8,584,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Assembly Biosciences by 12.2% during the 4th quarter. The Manufacturers Life Insurance Company now owns 12,371 shares of the biopharmaceutical company’s stock worth $560,000 after acquiring an additional 1,349 shares during the last quarter. American International Group Inc. lifted its holdings in shares of Assembly Biosciences by 15.4% during the 4th quarter. American International Group Inc. now owns 10,853 shares of the biopharmaceutical company’s stock worth $491,000 after acquiring an additional 1,450 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of Assembly Biosciences by 13.8% during the 3rd quarter. California Public Employees Retirement System now owns 27,925 shares of the biopharmaceutical company’s stock worth $975,000 after acquiring an additional 3,385 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Assembly Biosciences by 10.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 47,317 shares of the biopharmaceutical company’s stock worth $1,653,000 after acquiring an additional 4,330 shares during the last quarter. Finally, Teacher Retirement System of Texas bought a new stake in shares of Assembly Biosciences during the 4th quarter worth $242,000. 76.81% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Assembly Biosciences stock opened at $44.61 on Monday. Assembly Biosciences has a twelve month low of $18.60 and a twelve month high of $67.36.

A number of analysts have recently issued reports on the stock. ValuEngine raised shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Jefferies Group lifted their price objective on shares of Assembly Biosciences to $75.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. B. Riley assumed coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 price objective for the company. BidaskClub downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Finally, Zacks Investment Research downgraded shares of Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $54.25.

In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the business’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $56.37, for a total value of $56,370.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 3,000 shares of company stock valued at $152,550 over the last three months. 19.60% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Assembly Biosciences (ASMB) Shares Bought by Renaissance Technologies LLC” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/09/assembly-biosciences-asmb-shares-bought-by-renaissance-technologies-llc.html.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Want to see what other hedge funds are holding ASMB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Assembly Biosciences (NASDAQ:ASMB).

Institutional Ownership by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply